UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

517 Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

European journal of cancer (1990), 2015-09, Vol.51, p.S109-S109

2015

Volltextzugriff (PDF)

1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)

Annals of oncology, 2023-10, Vol.34, p.S652-S653

2023

Volltextzugriff (PDF)

1089P Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma

Annals of oncology, 2024-09, Vol.35, p.S720-S721

2024

Volltextzugriff (PDF)

1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma

Annals of oncology, 2023-10, Vol.34, p.S659-S659

2023

Volltextzugriff (PDF)

1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

Annals of oncology, 2023-10, Vol.34, p.S652-S652

2023

Volltextzugriff (PDF)

1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)

Annals of oncology, 2023-10, Vol.34, p.S680-S680

2023

Volltextzugriff (PDF)

71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial

Annals of oncology, 2024-09, Vol.35, p.S242-S242

2024

Volltextzugriff (PDF)

801P Neoadjuvant checkpoint inhibitor immunotherapy (IMT) for resectable mucosal melanoma (MM)

Annals of oncology, 2022-09, Vol.33, p.S910

2022

Volltextzugriff (PDF)

283MO Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort

Annals of oncology, 2022-09, Vol.33, p.S668-S669

2022

Volltextzugriff (PDF)

822P Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)

Annals of oncology, 2022-09, Vol.33, p.S923

2022

Volltextzugriff (PDF)

Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Annals of oncology, 2019-10, Vol.30, p.v555

2019

Volltextzugriff (PDF)

1360P - Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

Annals of oncology, 2019-10, Vol.30, p.v555-v555

2019

Volltextzugriff (PDF)

1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors

Annals of oncology, 2021-09, Vol.32, p.S899-S899

2021

Volltextzugriff (PDF)

Characteristics of metastatic melanoma (MM) patients with leptomeningeal disease (LMD) and survival of > 1 year

Annals of oncology, 2017-09, Vol.28, p.v444-v444

2017

Volltextzugriff (PDF)

1312PD - Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

Annals of oncology, 2019-10, Vol.30, p.v534-v535

2019

Volltextzugriff (PDF)

Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

Annals of oncology, 2019-10, Vol.30, p.v534-v535

2019

Volltextzugriff (PDF)

1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience

Annals of oncology, 2020-09, Vol.31, p.S756-S756

2020

Volltextzugriff (PDF)

Advances in the systemic treatment of melanoma brain metastases

Annals of oncology, 2018-07, Vol.29 (7), p.1509-1520

2018

Volltextzugriff (PDF)

A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)

Annals of oncology, 2018-10, Vol.29, p.viii464-viii464

2018

Volltextzugriff (PDF)

Opinions of Nurses on the Application and Implications of DNR/DNI Orders

Annals of oncology, 2012-09, Vol.23, p.ix517

2012

Volltextzugriff (PDF)

1605P - Opinions of Nurses on the Application and Implications of DNR/DNI Orders

Annals of oncology, 2012-09, Vol.23, p.ix517-ix517

2012

Volltextzugriff (PDF)

Longitudinal study of meningococcal carrier rates in teenagers

International journal of hygiene and environmental health, 2008-07, Vol.211 (3), p.263-272

2008

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

517 Long-term efficacy of intrathecal interleukin-2 (IT IL2) in metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

1085O Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)

1089P Longitudinal biomarker analysis and outcomes for patients (pts) treated with neoadjuvant nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma

1094P Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma

1082O Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)

1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)

71MO Clinical and biomarker analyses of intratumoral CD40 agonist sotigalimab in combination with pembrolizumab in metastatic melanoma: A phase I/II trial

801P Neoadjuvant checkpoint inhibitor immunotherapy (IMT) for resectable mucosal melanoma (MM)

283MO Leptomeningeal disease (LMD) in patients (pts) with metastatic melanoma (MM): Survival analysis of a contemporary cohort

822P Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM)

Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

1360P - Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: A multicenter, retrospective analysis

1085P Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors

Characteristics of metastatic melanoma (MM) patients with leptomeningeal disease (LMD) and survival of > 1 year

1312PD - Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

1124P Phase Ib study to evaluate the safety of selinexor (SEL) in combination with pembrolizumab (PEM) in patients with advanced malignancies- the: The melanoma experience

Advances in the systemic treatment of melanoma brain metastases

A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD)

Opinions of Nurses on the Application and Implications of DNR/DNI Orders

1605P - Opinions of Nurses on the Application and Implications of DNR/DNI Orders

Longitudinal study of meningococcal carrier rates in teenagers

Suchergebnisse filtern